Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2011-06-21
2011-06-21
Padmanabhan, Sreeni (Department: 1627)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C564S123000, C564S308000, C564S427000, C568S306000, C514S254070, C514S254100, C514S396000
Reexamination Certificate
active
07964648
ABSTRACT:
Methods for concomitant administration of colchicine together with one or more second active agents, e.g., ketoconazole and ritonavir, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. Methods of notifying health care practitioners and patients regarding appropriate dosing for concomitant administration of colchicine together with second active agents are also provided.
REFERENCES:
patent: 5426224 (1995-06-01), Lee et al.
patent: 5914332 (1999-06-01), Sham et al.
patent: 5968972 (1999-10-01), Broder et al.
patent: 6037157 (2000-03-01), Norbeck et al.
patent: 6245805 (2001-06-01), Broder et al.
patent: 6896900 (2005-05-01), Gosselin et al.
patent: 7601758 (2009-10-01), Davis
patent: 7619004 (2009-11-01), Davis
Wang et al. 2001, HMG-CoA reductase inhibitors (Statins) characterized as direct inhibitors of P-glycoprotein. Pharmaceutical Research, vol. 18, No. 6, pp. 800-806.
DRUGS.COM; “Drug Interactions Between Colchicine and Ketoconazole”; printed Dec. 4, 2009; 2 pages.
Horn, et al.; “Life-Threatening Colchicine Drug Interactions”; Pharmacy Times; pp. 111; (May 2006).
COLCYRS—Prescribing Information, www.colcrys.com/assets/pdf/COLCRYS—Full—Prescribing—Information.pdf; 5 pages; Revised Sep. 2009.
Niel, et al.; “Colchicine Today”; Joint Bone Spine; 73; pp. 672-678; (2006).
Perez-Ruiz, et al.; “Optimisation of the Treatment of Acute Gout”; BioDrugs; 13; pp. 415-423; (2000).
Terkeltaub, Robert A.; “Gout”; The New England Journal of Medicine; 349; pp. 1647-1655; (2003).
Terkeltaub, Robert A.; “Colchicine Update: 2008”; Semin. Arthritis Rheum. 38:411-419; (2009) (e publ. Oct. 29, 2008).
Terkeltaub, et al. (a); “Comparison of Low-Dose vs High-Dose Oral Colchicine Regimens in Patients with Gout Flares”; Presentation at the American College of Rheumatology Scientific Meeting: San Francisco, CA; 23 pages; Oct. 26; (2008).
Terkeltaub, et al. (b); “The Clinical Relevance of P-gp and CYP 3A4 on Colchicine Metabolism and Elimination”; Presentation at the American College of Rheumatology Scientific Meeting; San Francisco; CA; 19 pages; Oct. 26; (2008).
Ben-Chetrit and Levy; “Colchicine: 1998 Update”; Semin. Arthritis Rheum.; 28:48-59; (1998).
Leikin and Paloucek (eds.); “Colchicine”; Poisoning and Toxicology Handbook; 4th ed.; pp. 216-217; (CRC Press; (2008).
Ketoconazole Tablets UPS; Prescribing Information; Apotex, Inc.; 8 pages; Revised Jul. 2004.
Colchicine-Probenecid; http:///www.healthgrades.com/drug-ratings/drug/sideeffects/2207/colchecine-probenecid; 2 pages; printed Dec. 2, 2009.
U.S. Appl. No. 12/372,046, NonFinal Office Action dated May 18, 2009, 9 pages.
U.S. Appl. No. 12/372,046, NonFinal Office Action dated Jul. 14, 1009, 10 pages.
U.S. Appl. No. 12/372,046, Final Office Action dated Sep. 11, 2009, 24 pages.
Herrewege, et al.; “A Dual Chamber Model of Female Cervical Mucosa for the Study of HIV Transmission and for the Evaluation of Candidate HIV Microbicides”; Antiviral Research; 74; 111-124; (2007).
Hsu, et al; “Ritonavir; Clinical Pharmacokinetics and Interactions with Other Anti-HIV Agents”; Clinical Pharmacokinet; 35; pp. 275-291; (1998).
Krishnan et al; “Gout in Ambulatory Care Settings in the United States”; Journal of Rheumatology; 35; pp. 498-501; (2008).
Van Der Velden, et al; “Colchicine-Induced Neuromyopathy In A Patient With Chronic Renal Failure: The Role Of Clarithromycin”; Netherlands, The Journal Of Medicine; 66; pp. 204-206; (2008).
Zhou, et al; “Clinical Outcomes and Management of Mechanism-Based Inhibition of Cytochrome P450 3A4”; Therapeutics and Clinical Risk Management; 1; pp. 3-13; (2005).
U.S. Appl. No. 12/372,046, NonFinal Office Action dated Jan. 26, 2010, 30 pages.
Creighton, et al.; “Is Ritonavir Boosting Associated with Gout?”; Royal Society of Medicine Services, London, U.K.; 16; pp. 362-364; (2005).
Lacy et al., Lexi-Comp's Clinical Reference Library, Drug Information Handbook, 7th Ed., 1999-2000, pp. 108-109 and 292-293.
Drugs.com;“Colchicine Dosage” (available online http://www.drugs.com/dosage/colchicine.html); 6 pages; accessed Sep. 20, 2010.
Rx-s.net/weblog/more/colchicine-indications-and-dosage/; “Colchicine Indications and Dosage”; 5 pages; last revised Aug. 2, 2005.
Ogbru, Omudhome (www.medicinenet.com/colchicine/article.htm; 2 pages; (2008).
Rango; “Management of Gout With Colchicine”, http://www.theberries.ca/Archives/colchicine.html; 4 pages; available on line as of Jul. 5, 2003).
Cantor & Colburn LLP
McMillian Kara R
Mutual Pharmaceutical Company, Inc.
Padmanabhan Sreeni
LandOfFree
Methods for concomitant administration of colchicine and a... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for concomitant administration of colchicine and a..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for concomitant administration of colchicine and a... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2721402